PERSPECTIVE

Insights into Pancreatic Cancer Etiology: From Epidemiology to Molecular Pathways

Richard Lernmark*

Institute of Tissue Medicine and Pathology, University of Bern, Switzerland

Introduction

Pancreatic cancer remains one of the most challenging malignancies to treat, with a five-year survival rate of around 10%. Understanding the etiology of pancreatic cancer is crucial for developing effective prevention strategies and targeted therapies. While advances have been made in elucidating both environmental and genetic risk factors, the complex interplay between these factors and molecular pathways driving pancreatic carcinogenesis continues to be a focus of intense research. This review provides a comprehensive examination of insights into pancreatic cancer etiology, spanning epidemiological patterns, genetic predispositions, and key molecular pathways implicated in disease development and progression [1].

Epidemiological studies have identified several demographic and lifestyle factors associated with an increased risk of pancreatic cancer. Age is a significant risk factor, with the incidence of pancreatic cancer rising sharply after the age of 50, peaking in the seventh and eighth decades of life. Men have a slightly higher incidence of pancreatic cancer compared to women, although the reasons for this gender disparity remain unclear. Cigarette smoking is the most well-established environmental risk factor for pancreatic cancer, accounting for approximately 20-25% of cases [2].

Chronic pancreatitis, diabetes mellitus, obesity, and a family history of pancreatic cancer are also associated with an elevated risk of developing the disease. Geographic variation in pancreatic cancer incidence provides further insights into potential environmental risk factors. Regions with higher rates of cigarette smoking, obesity, and dietary habits rich in red and processed meats tend to have elevated pancreatic cancer incidence rates. Conversely, populations with lower rates of tobacco use and healthier dietary patterns exhibit lower pancreatic cancer incidence rates [3].

These observations underscore the importance of lifestyle modifications and public health initiatives in reducing the burden of pancreatic cancer on a global scale . While most cases of pancreatic cancer are sporadic, approximately 5-10% of cases are attributed to inherited genetic syndromes. Familial pancreatic cancer, defined by the presence of multiple affected family members without a known hereditary syndrome, accounts for a subset of cases with a familial predisposition. Studies have identified several germline mutations associated with familial pancreatic cancer, including mutations in genes such as BRCA1, BRCA2, PALB2, ATM, CDKN2A, and STK11 [4].

These genes are involved in DNA repair pathways, highlighting the importance of genomic stability in pancreatic carcinogenesis. Hereditary cancer syndromes, such as hereditary breast and ovarian cancer syndrome (caused by BRCA1 and BRCA2 mutations) and Lynch syndrome (caused by mismatch repair gene mutations), also increase the risk of pancreatic cancer. Individuals with these hereditary syndromes have a significantly elevated lifetime risk of developing pancreatic cancer compared to the general population [5].

Furthermore, recent genome-wide association studies (GWAS) have identified common susceptibility variants associated with pancreatic cancer risk, providing additional insights into the genetic architecture of the disease. Pancreatic carcinogenesis is driven by a complex interplay of genetic and epigenetic alterations affecting key signaling pathways involved in cell proliferation, survival, and differentiation [6].

The most frequently mutated gene in pancreatic cancer is KRAS, with activating mutations occurring in over 90% of cases. Oncogenic KRAS signaling promotes cell proliferation, survival, and metastasis through activation of downstream effector pathways such as MAPK and PI3K-AKT. In addition to KRAS mutations, inactivation of tumor suppressor genes such as TP53, CDKN2A, and SMAD4

Received 24-Jan-2024 Manuscript No ipp-24-19031 **Editor Assigned** 26-Jan-2024 PreQC No ipp-24-19031(PQ) **Reviewed** 9-Feb-2024 QC No ipp-24-19031 **Revised** 14-Feb-2024 Manuscript No ipp-24-19031(R) **Published** 21-Feb-2024 DOI 10.35841/1590-8577-25.1.845

Correspondence Richard Lernmark,
Institute of Tissue Medicine and Pathology,
University of Bern, Switzerland
E-mail Lernmark@swit.com

Citation: Lernmark R. Insights into Pancreatic Cancer Etiology: From Epidemiology to Molecular Pathways. JOP. J Pancreas. (2024) 25:845

plays a crucial role in pancreatic cancer pathogenesis [7].

The tumor microenvironment also plays a critical role in pancreatic carcinogenesis, with stromal components such as cancer-associated fibroblasts, immune cells, and extracellular matrix proteins contributing to tumor growth, invasion, and metastasis. Pancreatic stellate cells, activated in response to injury or inflammation, promote desmoplasia and create a fibrotic, immunosuppressive microenvironment conducive to tumor progression. Immune evasion mechanisms, including upregulation of immune checkpoint molecules such as PD-L1, enable pancreatic cancer cells to evade immune surveillance and facilitate tumor immune escape [8].

Despite significant progress in understanding the molecular pathways driving pancreatic carcinogenesis, therapeutic options for pancreatic cancer remain limited, with surgery representing the only potentially curative treatment modality for localized disease. Targeted therapies aimed at inhibiting oncogenic KRAS signaling, targeting DNA damage repair pathways, and modulating the tumor microenvironment hold promise for improving treatment outcomes in pancreatic cancer. However, challenges such as tumor heterogeneity, acquired resistance to therapy, and the presence of desmoplastic stroma complicate therapeutic development and limit treatment efficacy [9].

Immunotherapy has emerged as a promising treatment approach for pancreatic cancer, with immune checkpoint inhibitors demonstrating clinical activity in a subset of patients. Strategies to overcome immune evasion mechanisms and enhance the efficacy of immunotherapy in pancreatic cancer are actively being pursued, including combination approaches with chemotherapy, targeted therapy, and other immunomodulatory agents. Personalized medicine approaches based on genomic profiling and molecular subtyping hold promise for identifying patient-specific vulnerabilities and tailoring treatment regimens to individual tumor characteristics [10].

Conclusion

Insights into the etiology of pancreatic cancer have advanced significantly in recent years, with epidemiological studies elucidating demographic and lifestyle factors associated with disease risk, genetic analyses identifying germline and somatic mutations predisposing to pancreatic cancer, and molecular studies unraveling the complex signaling pathways driving pancreatic carcinogenesis. Integrating these insights into clinical practice holds promise for improving risk stratification, early detection, and treatment outcomes in pancreatic cancer. Continued research efforts aimed at unraveling the molecular mechanisms underlying pancreatic carcinogenesis and translating these findings into clinically actionable strategies are essential for reducing the global burden of this devastating disease.

References

1. Wei MY, Shi S, Liang C, Meng QC, Hua J, Zhang YY, et al. The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol Cancer. 2019;18(1):1-5. [PMID: 31109338]

2. Zhao Y, Tang J, Jiang K, Liu SY, Aicher A, Heeschen C. Liquid biopsy in pancreatic cancer–Current perspective and future outlook. Biochim Biophys Acta Rev Cancer. 2023:188868. [PMID: 36842769]

3. Mallya K, Gautam SK, Aithal A, Batra SK, Jain M. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188554. [PMID: 33945847]

4. Mere Del Aguila E, Tang XH, Gudas LJ. Pancreatic ductal adenocarcinoma: new insights into the actions of vitamin A. Oncol Res Treat. 2022;45(5):291-8. [PMID: 35130553]

5. Wood LD, Yurgelun MB, Goggins MG. Genetics of familial and sporadic pancreatic cancer. Gastroenterology. 2019;156(7):2041-55. [PMID: 30660730]

6. Subhan M, Parel NS, Krishna PV, Gupta A, Uthayaseelan K, Uthayaseelan K, et al. Smoking and Pancreatic Cancer: Smoking Patterns, Tobacco Type, and Dose-Response Relationship. Cureu. 2022;14(6). [PMID: 35859955]

7. Cuyler J, Murthy P, Spada NG, McGuire TF, Lotze MT, Xie XQ. Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Drug Discov Today. 2022;27(1):362-70. [PMID: 34592447]

8. Taherian M, Wang H, Wang H. Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. Cells. 2022;11(19):3068. [PMID: 36231030]

9. Wang Y, Yang G, You L, Yang J, Feng M, Qiu J, et al. Role of the microbiome in occurrence, development and treatment of pancreatic cancer. Mol Cancer. 2019;18(1):1-3. [PMID: 31785619]

10. Karamitopoulou E. Emerging prognostic and predictive factors in pancreatic cancer. Mod Pathol. 2023:100328. [PMID: 37714333]

Citation: Lernmark R. Insights into Pancreatic Cancer Etiology: From Epidemiology to Molecular Pathways. JOP. J Pancreas. (2024) 25:845